Synairgen Regulatory News (SNG)

Synairgen plc

('Synairgen' or the 'Company')

Appointment of Joint Broker

Southampton, UK - 2 October 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce the appointment of Numis Securities Limited as Joint Broker to the Company with immediate effect. finnCap remains Nominated Adviser and Joint Broker to the Company.

-Ends

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap (Nominated Advisor & Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield

Tel: +44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media & Investor Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

Notes for Editors

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of

Southampton Professors Stephen Holgate, Donna Davies, and Ratko Djukanovic. The

business, focused primarily on lung viral defence in asthma, COPD, and COVID-19, uses its

differentiating human biology BioBank platform and world-renowned international academic

KOL network to discover and develop novel therapies for respiratory disease. Synairgen is

quoted on AIM (LSE: SNG). For more information about Synairgen, please see

https://www.synairgen.com